JP2008531609A5 - - Google Patents

Download PDF

Info

Publication number
JP2008531609A5
JP2008531609A5 JP2007557330A JP2007557330A JP2008531609A5 JP 2008531609 A5 JP2008531609 A5 JP 2008531609A5 JP 2007557330 A JP2007557330 A JP 2007557330A JP 2007557330 A JP2007557330 A JP 2007557330A JP 2008531609 A5 JP2008531609 A5 JP 2008531609A5
Authority
JP
Japan
Prior art keywords
methyl
prop
alkyl
dimethyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007557330A
Other languages
English (en)
Other versions
JP2008531609A (ja
JP5237643B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2006/000123 external-priority patent/WO2006092143A1/en
Publication of JP2008531609A publication Critical patent/JP2008531609A/ja
Publication of JP2008531609A5 publication Critical patent/JP2008531609A5/ja
Application granted granted Critical
Publication of JP5237643B2 publication Critical patent/JP5237643B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

「C1−6−アルキル(アルケニル/アルキニル)」という表現は、C1−6−アルキル、C2−6−アルケニルまたはC2−6−アルキニル基を意味する。「C1−6−アルキル」という語句は、メチル、エチル、プロパ−1−イル、プロパ−2−イル、2−メチル−プロパ−1−イル、2−メチル−プロパ−2−イル、2,2−ジメチル−プロパ−1−イル、ブタ−1−イル、ブタ−2−イル、3−メチル−ブタ−1−イル、3−メチル−ブタ−2−イル、ペンタ−1−イル、ペンタ−2−イル、ペンタ−3−イル、ヘキサ−1−イル、ヘキサ−2−イルおよびヘキサ−3−イルを含むがこれらに限定されない、1〜6個の炭素原子を有する分岐または非分岐のアルキル基を示す。「C2−6−アルケニル」という語句は、エテニル、プロペニルおよびブテニルを含むがこれらに限定されない、2〜6個の炭素原子および1個の二重結合を有する分岐または非分岐のアルケニル基を示す。
「C1−8−アルキル(アルケニル/アルキニル)」という表現は、C1−8−アルキル、C2−8−アルケニルまたはC2−8−アルキニルを意味する。「C1−8−アルキル」という語句は、限定はされないがメチル、エチル、プロパ−1−イル、プロパ−2−イル、2−メチル−プロパ−1−イル、2−メチル−プロパ−2−イル、2,2−ジメチル−プロパ−1−イル、ブタ−1−イル、ブタ−2−イル、3−メチル−ブタ−1−イル、3−メチル−ブタ−2−イル、ペンタ−1−イル、ペンタ−2−イル、ペンタ−3−イル、ヘキサ−1−イル、ヘキサ−2−イル、ヘキサ−3−イル、2−メチル−4,4−ジメチル−ペンタ−1−イルおよびヘプタ−1−イルを含む、1〜8個の炭素原子を有する分岐または非分岐アルキル基を示す。
Figure 2008531609
これらの化合物はそれぞれが特定の実施態様であり、個々の請求項に含めることもできるものである。
1aw 2−シクロヘキサ−1−エニル−N−(2,4−ジメチル−6−モルホリン−4−イル−ピリジン−3−イル)−アセトアミド
収率:13%。LC−MS(m/z)330(MH);t=1.50,(UV,ELSD)72%,99%。
1be 2−ビシクロ[2.2.1]ヘプタ−2−イル−N−(2,4−ジメチル−6−モルホリン−4−イル−ピリジン−3−イル)−アセトアミド
収率:62%。LC−MS(m/z)344(MH);t=1.58,(UV,ELSD)99%,99%。HNMR(500MHz,DMSO−d):1.14(m,4H),1.42(m,4H),1.90(m,1H),2.01(m,1H),2.04(s,3H),2.10(m,1H),2.16(s,3H),2.21(m,2H),3.37(m,4H),3.67(m,4H),6.53(s,1H),9.04(s,1H)。
1bh 2−シクロペンタ−2−エニル−N−(2,4−ジメチル−6−モルホリン−4−イル−ピリジン−3−イル)−アセトアミド
収率:13%。LC−MS(m/z)316(MH);t=1.25,(UV,ELSD)97%,94%。HNMR(500MHz,DMSO−d):1.51(m,1H),2.05(m,1H),2.06(s,3H),2.17(s,3H),2.26(m,2H),2.35(m,2H),3.07(m,1H),3.38(m,4H),3.68(m,4H),5.73(m,1H),5.77(m,1H),6.54(s,1H),9.09(s,1H)。

Claims (1)

  1. 前記化合物が以下:
    Figure 2008531609
    からなる群から選択される、請求項1〜10のいずれか1つに記載の遊離塩基またはその塩としての化合物。
JP2007557330A 2005-03-03 2006-03-02 置換されたピリジン誘導体 Expired - Fee Related JP5237643B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US65842805P 2005-03-03 2005-03-03
US60/658,428 2005-03-03
DKPA200500321 2005-03-03
DKPA200500321 2005-03-03
PCT/DK2006/000123 WO2006092143A1 (en) 2005-03-03 2006-03-02 Substituted pyridine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013036417A Division JP5705249B2 (ja) 2005-03-03 2013-02-26 置換されたピリジン誘導体

Publications (3)

Publication Number Publication Date
JP2008531609A JP2008531609A (ja) 2008-08-14
JP2008531609A5 true JP2008531609A5 (ja) 2012-02-02
JP5237643B2 JP5237643B2 (ja) 2013-07-17

Family

ID=36544250

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007557330A Expired - Fee Related JP5237643B2 (ja) 2005-03-03 2006-03-02 置換されたピリジン誘導体
JP2013036417A Expired - Fee Related JP5705249B2 (ja) 2005-03-03 2013-02-26 置換されたピリジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013036417A Expired - Fee Related JP5705249B2 (ja) 2005-03-03 2013-02-26 置換されたピリジン誘導体

Country Status (11)

Country Link
US (2) US7812020B2 (ja)
EP (2) EP1861394A1 (ja)
JP (2) JP5237643B2 (ja)
AU (1) AU2006220130B2 (ja)
CA (1) CA2599890C (ja)
CY (1) CY1114561T1 (ja)
HR (1) HRP20130973T1 (ja)
MX (1) MX2007010547A (ja)
NO (1) NO20074959L (ja)
PL (1) PL2298766T3 (ja)
WO (1) WO2006092143A1 (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799832B2 (en) 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
EP1861394A1 (en) * 2005-03-03 2007-12-05 H.Lundbeck A/S Substituted pyridine derivatives
US20070078177A1 (en) * 2005-09-30 2007-04-05 Washington University In St. Louis Methods and compositions for treating non age related hearing impairment in a subject
TWI453013B (zh) * 2006-02-07 2014-09-21 Lundbeck & Co As H N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
CA2661462C (en) 2006-08-23 2015-09-29 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
MX2009005652A (es) 2006-11-28 2009-08-07 Valeant Pharmaceuticals Int Analogos 1,4 diamino biciclicos de retigabina como moduladores de canales de potasio.
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US20100256145A1 (en) * 2007-08-01 2010-10-07 H. Lundbeck A/S Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2010094644A1 (en) 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
WO2010094645A1 (en) 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
WO2010097379A1 (en) 2009-02-24 2010-09-02 Neurosearch A/S Substituted pyrimidin derivatives and their medical use
TWI504395B (zh) 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
TW201038565A (en) * 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI461197B (zh) 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
US20120238547A1 (en) 2009-09-07 2012-09-20 Neurosearch A/S 2, 3, 6 - triamino substituted pyridines as kv7 (kcnq) channel modulators
WO2011026891A1 (en) 2009-09-07 2011-03-10 Neurosearch A/S Substituted pyridine derivatives and their medical use
NZ604745A (en) 2010-08-27 2015-01-30 Gruenenthal Chemie Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators
US8470852B2 (en) 2010-08-27 2013-06-25 Gruenenthal Gmbh Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators
EP2609086B1 (en) 2010-08-27 2015-02-25 Grünenthal GmbH Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators
MX2013002295A (es) 2010-09-01 2013-05-09 Gruenenthal Gmbh 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
KR101820645B1 (ko) * 2010-10-20 2018-01-22 그뤼넨탈 게엠베하 Kcnq2/3 조절제로서의 치환된 6­아미노­니코틴아미드
AU2015201122B2 (en) * 2010-10-20 2016-02-25 Grunenthal Gmbh Substituted 6-amino-nicotinamides as KCNQ2/3 modulators
US9168259B2 (en) * 2010-10-20 2015-10-27 Grünenthal GmbH Substituted 6-amino-nicotinamides as KCNQ2/3 modulators
CA2839350A1 (en) 2011-07-05 2013-01-10 Contera Pharma Aps The use of serotonin receptor agonists for treatment of movement disorders
AU2013248638A1 (en) 2012-04-18 2014-12-04 Grünenthal GmbH Substituted 4-aminobenzamides as KCNQ2/3 modulators
CA2950469C (en) 2014-06-26 2022-09-20 Contera Pharma Aps Use of buspirone metabolites
JP7100125B2 (ja) * 2017-10-27 2022-07-12 フレゼニウス・カビ・オンコロジー・リミテッド リボシクリブおよびその塩の改善された調製のためのプロセス

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
WO1996021644A1 (en) * 1995-01-10 1996-07-18 Smithkline Beecham S.P.A. Indole derivatives useful in the treatment of osteoporosis
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
EP1033366A3 (en) * 1999-02-18 2000-12-27 Pfizer Products Inc. Amide derivatives useful as Neuropeptide Y (NPY) antagonists
US6407120B1 (en) 1999-02-18 2002-06-18 Pfizer Inc. Neuropeptide Y antagonists
DE60037321T4 (de) * 1999-08-04 2010-01-07 Icagen, Inc. Benzanilide als öffner des kaliumkanals
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
WO2001092526A1 (en) 2000-05-26 2001-12-06 Bristol-Myers Squibb Company Human kcnq5 potassium channel, methods and compositions thereof
WO2001096540A2 (en) 2000-06-11 2001-12-20 Dupont Pharmaceuticals Company Hepatitis c protease exosite for inhibitor design
US6589986B2 (en) 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
EP1361879A1 (en) * 2001-02-20 2003-11-19 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
JP2003206230A (ja) * 2002-01-10 2003-07-22 Yamanouchi Pharmaceut Co Ltd シアノヘテロ環誘導体又はその塩
US7906537B2 (en) 2003-03-21 2011-03-15 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
EP1861394A1 (en) * 2005-03-03 2007-12-05 H.Lundbeck A/S Substituted pyridine derivatives

Similar Documents

Publication Publication Date Title
JP2008531609A5 (ja)
JP2010535870A5 (ja)
AP1270A (en) Certain 1, 4, 5-Tri-substituted imidazole compounds useful as cytokine.
JP2010534247A5 (ja)
PE20060878A1 (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
SE0200411D0 (sv) Novel use
JP2010536766A5 (ja)
JP2007518682A5 (ja)
JP2008519087A5 (ja)
PE20050077A1 (es) Derivados de 4-pirrolidino-fenil-bencil-eter
UA84462C2 (ru) Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
JP2008526897A5 (ja)
JP2009501746A5 (ja)
JP2010517990A5 (ja)
RU2010145171A (ru) Аналоги галихондрина в
CA2556463A1 (en) Dihydropyridinone derivatives
JP2008526724A5 (ja)
JP2013531074A5 (ja)
ATE502936T1 (de) 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten
EP2865678A3 (en) Crystalline hemi-tartrate form of a benzoimidazol-2-yl pyrimidine derivative
JP2010500432A5 (ja)
JP2010536713A5 (ja)
JP2008538113A5 (ja)
JP2006527285A5 (ja)